United Therapeutics, a Maryland biotech company, has appointed head and neck surgeon Dr Linda Maxwell to its board of directors as an independent director.

Dr Linda Maxwell is also a medical educator, a health technology entrepreneur and innovator, and a published scientific author. She is an adjunct professor of surgery at the University of Toronto, an associate scientist at the Li Ka Shing Knowledge Institute in Toronto, and a visiting professor at Ryerson University.

Dr Linda Maxwell got an A.B. with honors from Harvard University, an M.D. from Yale University, followed by an M.B.A. from the University of Oxford. She is an independent member of the board of directors of Profound Medical, a publicly-traded company listed in both Canada and the US.

Martine Rothblatt – Chairman and CEO of United Therapeutics said: “We greatly value Dr. Maxwell’s outstanding achievements and experience.

“Her knowledge and business expertise position her well to serve on our Board of Directors.”

United Therapeutics, through its fully-owned subsidiary – Lung Biotechnology, is engaged in addressing the acute shortage of transplantable lungs and other organs in the US with a range of technologies that either delay the requirement for such organs or expand the supply.

Dr Linda Maxwell said: “I am thrilled to join the United Therapeutics family as an independent director.

“It is a privilege to join an extraordinary organization tackling some of the most pernicious problems in medicine through scientific ingenuity, visionary leadership, and a singular commitment to advancing human health.”

  Dr Linda Maxwel, Martine Rothblatt, Maryland, United Therapeutics, USA